1、公司不存在《管理办法》等法律、法规规定的禁止实施限制性股票激励 计划的情形，包括：（1）最近一个会计年度财务会计报告被注册会计师出具否 定意见或者无法表示意见的审计报告；（2）最近一个会计年度财务报告内部控 制被注册会计师出具否定意见或无法表示意见的审计报告；（3）上市后最近 36 个月内出现过未按法律法规、公司章程、公开承诺进行利润分配的情形；（4） 法律法规规定不得实行股权激励的；（5）中国证监会认定的其他情形。公司具 备实施限制性股票激励计划的主体资格。 2、公司 2025 年 A 股限制性股票激励计划所确定的激励对象不存在下列情 形：（1）最近 12 个月内被证券交易所认定为不适当人选；（2）最近 12 个月内 被中国证监会及其派出机构认定为不适当人选；（3）最近 12 个月内因重大违法 违规行为被中国证监会及其派出机构行政处罚或者采取市场禁入措施；（4）具 有《公司法》规定的不得担任公司董事、高级管理人员情形的；（5）法律法规 规定不得参与上市公司股权激励的；（6）中国证监会认定的其他情形。 的核查意见 康希诺生物股份公司（以下简称"公司"）监事会依据《中华人民共和国公司 法》（以下简称"《公司 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-024 康希诺生物股份公司 第三届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届监事会第九次会议于 2025 年 9 月 26 日在公司会议室以现场及通讯的方式召开。会议通知已于会议召开 5 日 前以电子邮件形式送达全体监事。本次会议由监事会主席肖治召集，应到监事 3 人，实到监事 3 人。会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律法规及规范性文件和《康希诺生物股份公司章程》（以下简称"《公司章 程》"）的规定，合法有效。 二、监事会会议审议情况 经与会监事审议，逐项表决，形成决议如下： （一）《关于公司<2025 年 A 股限制性股票激励计划（草案）>及其摘要的 议案》 监事会认为：公司《2025 年 A 股限制性股票激励计划（草案）》及其摘要的 内容符合《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《上海证券交易 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-023 康希诺生物股份公司 第三届董事会第二次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届董事会第二次临时会议于 2025 年 9 月 26 日在公司会议室以现场及通讯的方式召开。会议通知已于会议召 开 5 日前以电子邮件形式送达全体董事。本次会议由董事长 XUEFENG YU（宇学 峰）博士主持，应到董事 7 人，实到董事 7 人。会议的召集、召开和表决程序符 合《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规及规范性 文件和《康希诺生物股份公司章程》（以下简称"《公司章程》"）的规定，合 法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）《关于公司<2025 年 A 股限制性股票激励计划（草案）>及其摘要的 议案》 为了进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动 公司员工的积极性，有效地将股东利益、公司利益 ...

截至发稿，康希诺市值为189亿元。 每经AI快讯，康希诺（SH 688185，收盘价：76.4元）9月26日晚间发布公告称，公司第三届第二次董事 会临时会议于2025年9月26日在公司会议室以现场及通讯的方式召开。会议审议了《关于公司<2025年A 股限制性股票激励计划（草案）>及其摘要的议案》等文件。 2024年1至12月份，康希诺的营业收入构成为：生物医药占比97.47%，其他业务占比2.53%。 每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ （记者 王晓波） ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Group 1: Pharmaceutical Industry - The active pharmaceutical ingredient (API) industry has experienced a downturn over the past four years, with prices of various products, including sartans, heparins, and animal health products, reaching historical lows, leading to some leading companies operating at a loss [7][8][10] - In the first half of 2025, the API sector saw a decline in both revenue and net profit due to significant price drops in anti-infective products and increased R&D investments by some companies [7][10] - Domestic API companies are actively transitioning to innovative drug development, with several products in various clinical trial stages, indicating a shift towards higher-value offerings [7][10] Group 2: Real Estate Industry - The stabilization of housing prices is influenced by multiple factors, including monetary policy, supply-demand relationships, and economic expectations, rather than solely by population changes [3][12][15] - Analysis of housing price data from 70 cities shows that both new and second-hand housing prices have been in a downward trend since 2022, with a recent narrowing of year-on-year declines due to supportive policies [12][13] - Recommendations for investment focus on strong credit real estate companies with good fundamentals and leading product capabilities, as well as those benefiting from dual-driven residential and commercial real estate strategies [15] Group 3: IT Services Industry - The company is a leading player in the domestic IT services sector and a key partner of Huawei, with over 40% of its revenue derived from this partnership [4][17][20] - The company's cloud intelligence business is experiencing significant growth, and it is expected to benefit from the development of the HarmonyOS ecosystem and AI technologies [4][17][20] - Profit forecasts for 2025-2027 have been adjusted, with expected net profits of 564 million, 628 million, and 708 million yuan respectively, reflecting a strategic focus on AI and cloud services [4][17][20] Group 4: Alibaba Group - Alibaba is actively advancing its AI infrastructure and plans to increase investments, which is expected to accelerate growth in its cloud business [5][21][22] - The demand for AI infrastructure is exceeding expectations, with plans to invest 380 billion yuan in building AI infrastructure, significantly increasing the energy consumption scale of its global data centers by 10 times by 2032 [5][21][22] - The company aims to enhance its market position through comprehensive AI-driven strategies, including improvements in its e-commerce platform and cloud services [21][22][23]

Group 1 - The real estate sector showed weakness at the beginning of trading, with several companies experiencing significant declines [1] - Notable companies that hit the limit down include Shoukai Co., Xiangjiang Holdings, and ST Nanzhi, among others [1] - Other companies that followed the downward trend include Zhujiang Co., Huachao City A, Wolong New Energy, and Jintou Chengkai [1]

Core Viewpoint - The innovative drug sector is currently experiencing a phase of adjustment, with significant fluctuations in stock prices and ongoing capital inflows into the market [1][3][5]. Group 1: Market Performance - On September 19, A-share market saw a decline in innovative drug stocks, with Kanghong Pharmaceutical down 6% and Xinlitai and Kelun Pharmaceutical dropping over 3.8% [1]. - The Hong Kong Stock Connect innovative drug ETF (520880) opened high but closed lower, with a decline of 1.58% and a trading volume of 335 million yuan [1]. - The ETF has seen continuous capital inflow for 13 days, totaling over 670 million yuan as of September 18 [3]. Group 2: Investment Opportunities - Despite short-term volatility, the long-term logic of the innovative drug sector remains intact, with no substantial negative news impacting the market [5]. - The current macroeconomic environment is favorable, with the Federal Reserve restarting its interest rate cut cycle, which may benefit the global pharmaceutical sector [5][6]. - The trend of innovative drugs is clear, with several products entering advanced negotiation stages for overseas markets, potentially leading to continuous cash flow [6]. Group 3: ETF Adjustments - The Hong Kong Stock Connect innovative drug ETF (520880) has undergone a "purification" revision, completely excluding CXO companies and focusing solely on innovative drug R&D firms [6][7]. - As of September 5, the ETF had achieved a year-to-date increase of 119.75%, outperforming other innovative drug indices [7][8]. - The ETF is the first in the market to track the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, with a fund size exceeding 1.7 billion yuan and the highest liquidity among similar products [8].

中国经济网北京9月19日讯 康希诺(688185.SH)今日收报79.84元，跌幅2.63%。 康希诺募集资金总额为52.01亿元，扣除发行费用后，募集资金净额为49.79亿元。康希诺最终募集 资金净额较原计划多39.79亿元。康希诺2020年8月6日发布的招股说明书显示，公司计划募集资金10亿 元，分别用于"生产基地二期建设""在研疫苗开发""疫苗追溯、冷链物流体系及信息系统建设""补充流 动资金"。 康希诺上市发行费用为2.21亿元，其中保荐及承销费用2.05亿元。 中信证券投资有限公司（参与跟投的保荐机构相关公司）获配股票数量为49.60万股，占本次发行 总股数的2.00%，跟投金额为1.04亿元。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐 机构（主承销商）为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为 渤海证券。目前该股处于破发状态。 （责任编辑：关婧） ...

Core Viewpoint - 康希诺's stock price has shown volatility with a year-to-date increase of 33.84%, but recent trading indicates a slight decline in the short term [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 3.82 billion yuan for the first half of 2025, reflecting a year-on-year growth of 26.00% [2]. - The company experienced a net profit loss of 1348.54 million yuan, which is an improvement of 94.02% compared to the previous period [2]. Stock Market Activity - On September 17, 康希诺's stock price decreased by 2.07%, trading at 81.71 yuan per share with a total market capitalization of 202.19 billion yuan [1]. - The stock saw a net outflow of 616.01 million yuan in principal funds, with significant selling pressure from large orders [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period [2]. - The average number of circulating shares per shareholder remained at 0 [2]. Dividend Information - 康希诺 has distributed a total of 1.98 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].